Photodermatology, Photoimmunology & Photomedicine, ISSN 0905-4383, 10/2010, Volume 26, Issue 5, pp. 261 - 262
The majority of patients with psoriasis benefit from ultraviolet radiation exposure, but psoriasis can deteriorate on exposure to sunlight in some people. We...
ultraviolet radiation | photoaggravated psoriasis | palmoplantar psoriasis | photosensitivity | Photosensitivity | Photoaggravated psoriasis | Ultraviolet radiation | Palmoplantar psoriasis | PHOTOSENSITIVE PSORIASIS | DERMATOLOGY | Sunlight - adverse effects | Hand Dermatoses - complications | Foot Dermatoses - complications | Humans | Photosensitivity Disorders - complications | Male | Aged | Psoriasis - complications | Psoriasis | Radiation | U.V. radiation | Sunlight | Evolution | Hand | Foot
ultraviolet radiation | photoaggravated psoriasis | palmoplantar psoriasis | photosensitivity | Photosensitivity | Photoaggravated psoriasis | Ultraviolet radiation | Palmoplantar psoriasis | PHOTOSENSITIVE PSORIASIS | DERMATOLOGY | Sunlight - adverse effects | Hand Dermatoses - complications | Foot Dermatoses - complications | Humans | Photosensitivity Disorders - complications | Male | Aged | Psoriasis - complications | Psoriasis | Radiation | U.V. radiation | Sunlight | Evolution | Hand | Foot
Journal Article
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, ISSN 0190-9622, 03/2017, Volume 76, Issue 3, pp. 405 - 417
Background: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. Objectives: We...
TO-SEVERE PSORIASIS | scalp psoriasis | USTEKINUMAB | INTERLEUKIN-23 | CYTOKINE | INNATE LYMPHOID-CELLS | guselkumab | adalimumab | efficacy | hand and foot psoriasis | DERMATOLOGY | THERAPY | nail psoriasis | VOYAGE 2 | VOYAGE 1 | psoriasis | safety | SEVERE PLAQUE PSORIASIS | QUALITY-OF-LIFE | LONG-TERM EFFICACY
TO-SEVERE PSORIASIS | scalp psoriasis | USTEKINUMAB | INTERLEUKIN-23 | CYTOKINE | INNATE LYMPHOID-CELLS | guselkumab | adalimumab | efficacy | hand and foot psoriasis | DERMATOLOGY | THERAPY | nail psoriasis | VOYAGE 2 | VOYAGE 1 | psoriasis | safety | SEVERE PLAQUE PSORIASIS | QUALITY-OF-LIFE | LONG-TERM EFFICACY
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 76, Issue 3, pp. 405 - 417
Background Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. Objectives We sought...
Dermatology | nail psoriasis | VOYAGE 2 | VOYAGE 1 | psoriasis | safety | scalp psoriasis | guselkumab | adalimumab | efficacy | hand and foot psoriasis | Severity of Illness Index | Psoriasis - drug therapy | Double-Blind Method | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Dermatologic Agents - therapeutic use | Dermatologic Agents - adverse effects | Adalimumab - adverse effects | Adalimumab - therapeutic use | Interleukin-23 - antagonists & inhibitors | Placebos | Quality of Life | Adult | Female | Care and treatment | Interleukins | Clinical trials | Monoclonal antibodies | Skin diseases | Skin | Comparative analysis
Dermatology | nail psoriasis | VOYAGE 2 | VOYAGE 1 | psoriasis | safety | scalp psoriasis | guselkumab | adalimumab | efficacy | hand and foot psoriasis | Severity of Illness Index | Psoriasis - drug therapy | Double-Blind Method | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Dermatologic Agents - therapeutic use | Dermatologic Agents - adverse effects | Adalimumab - adverse effects | Adalimumab - therapeutic use | Interleukin-23 - antagonists & inhibitors | Placebos | Quality of Life | Adult | Female | Care and treatment | Interleukins | Clinical trials | Monoclonal antibodies | Skin diseases | Skin | Comparative analysis
Journal Article
Journal of drugs in dermatology : JDD, ISSN 1545-9616, 2006, Volume 5, Issue 9, pp. 838 - 846
Hand and foot psoriasis can appear in a plaque-type or pustular-type form. Any form of psoriasis that occurs on the hands and feet can have a debilitating...
Severity of Illness Index | Psoriasis - drug therapy | Foot Dermatoses - drug therapy | Humans | Middle Aged | Foot Dermatoses - pathology | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Hand Dermatoses - drug therapy | CD11 Antigens - immunology | Hand Dermatoses - pathology | Psoriasis - pathology | Antibodies, Monoclonal - administration & dosage | Aged, 80 and over | Adult | Female | Aged
Severity of Illness Index | Psoriasis - drug therapy | Foot Dermatoses - drug therapy | Humans | Middle Aged | Foot Dermatoses - pathology | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Hand Dermatoses - drug therapy | CD11 Antigens - immunology | Hand Dermatoses - pathology | Psoriasis - pathology | Antibodies, Monoclonal - administration & dosage | Aged, 80 and over | Adult | Female | Aged
Journal Article
Dermatology Online Journal, 2010, Volume 16, Issue 7, p. 8
Hand and foot psoriasis is a disabling condition associated with significant quality-of-life issues. It is characterized by hyperkeratosis and/or the...
Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Dermatologic Agents - therapeutic use | Hepatitis C, Chronic - complications | Methotrexate - therapeutic use | Hand Dermatoses - drug therapy | Psoriasis - complications | Hand Dermatoses - pathology | Retinoids - therapeutic use | Infliximab | Psoriasis - pathology | DiGeorge Syndrome - complications | Foot Dermatoses - complications | Adult | Female | Retrospective Studies | Psoriasis - drug therapy | Foot Dermatoses - drug therapy | Foot Dermatoses - pathology | Treatment Outcome | Fatty Liver, Alcoholic - complications | Cyclosporine - therapeutic use | Hand Dermatoses - complications
Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Dermatologic Agents - therapeutic use | Hepatitis C, Chronic - complications | Methotrexate - therapeutic use | Hand Dermatoses - drug therapy | Psoriasis - complications | Hand Dermatoses - pathology | Retinoids - therapeutic use | Infliximab | Psoriasis - pathology | DiGeorge Syndrome - complications | Foot Dermatoses - complications | Adult | Female | Retrospective Studies | Psoriasis - drug therapy | Foot Dermatoses - drug therapy | Foot Dermatoses - pathology | Treatment Outcome | Fatty Liver, Alcoholic - complications | Cyclosporine - therapeutic use | Hand Dermatoses - complications
Journal Article
American Journal of Clinical Dermatology, ISSN 1175-0561, 2008, Volume 9, Issue 2, pp. 105 - 109
Introduction: Hand and foot psoriasis may be more disabling than psoriasis at other body locations because of its interference with daily functional...
Efalizumab, therapeutic use | Psoriasis, treatment | TRIAL | PUSTULOSIS | THERAPY | CHRONIC PLAQUE PSORIASIS | RECALCITRANT PALMOPLANTAR | FOLLOW-UP | INFLIXIMAB | CANCER | DERMATOLOGY | Recurrence | Psoriasis - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Immunologic Factors - administration & dosage | Male | Treatment Outcome | Hand - pathology | Psoriasis - pathology | Antibodies, Monoclonal - administration & dosage | Injections, Subcutaneous | Quality of Life | Adult | Female | Aged | Immunologic Factors - adverse effects | Foot - pathology | Skin - pathology
Efalizumab, therapeutic use | Psoriasis, treatment | TRIAL | PUSTULOSIS | THERAPY | CHRONIC PLAQUE PSORIASIS | RECALCITRANT PALMOPLANTAR | FOLLOW-UP | INFLIXIMAB | CANCER | DERMATOLOGY | Recurrence | Psoriasis - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Immunologic Factors - administration & dosage | Male | Treatment Outcome | Hand - pathology | Psoriasis - pathology | Antibodies, Monoclonal - administration & dosage | Injections, Subcutaneous | Quality of Life | Adult | Female | Aged | Immunologic Factors - adverse effects | Foot - pathology | Skin - pathology
Journal Article
Journal of drugs in dermatology : JDD, ISSN 1545-9616, 2007, Volume 6, Issue 12, pp. 1224 - 1230
Psoriasis of the hands and feet is highly debilitating and difficult to treat. It may be of a plaque-or pustular-type, or a combination of the two. Efalizumab...
Psoriasis - drug therapy | Foot Dermatoses - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Foot Dermatoses - pathology | Antibodies, Monoclonal - therapeutic use | Male | Hand Dermatoses - drug therapy | Hand Dermatoses - pathology | Injections | Psoriasis - pathology | Adult | Female | Aged | Immunologic Factors - adverse effects | Immunologic Factors - therapeutic use
Psoriasis - drug therapy | Foot Dermatoses - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Foot Dermatoses - pathology | Antibodies, Monoclonal - therapeutic use | Male | Hand Dermatoses - drug therapy | Hand Dermatoses - pathology | Injections | Psoriasis - pathology | Adult | Female | Aged | Immunologic Factors - adverse effects | Immunologic Factors - therapeutic use
Journal Article
Dermatology nursing / Dermatology Nurses' Association, ISSN 1060-3441, 08/2008, Volume 20, Issue 4, pp. 291 - 293
Hand and foot psoriasis impairs patients' ability to function, impacts them financially, and chips away at their self-worth. Dermatology nurses play an...
Severity of Illness Index | Activities of Daily Living - psychology | Foot Dermatoses - psychology | Hand Dermatoses - therapy | Nurse's Role | Attitude to Health | Foot Dermatoses - diagnosis | Foot Dermatoses - therapy | Humans | Psoriasis - diagnosis | Cost of Illness | Antibodies, Monoclonal - therapeutic use | Psoriasis - psychology | Hand Dermatoses - psychology | Health Services Needs and Demand | Mass Screening | Self Concept | Quality of Life - psychology | Hand Dermatoses - diagnosis | Nursing Assessment | Psoriasis - therapy | Services | Care and treatment | Psoriasis | Nurses | Analysis | Diagnosis | Quality of life
Severity of Illness Index | Activities of Daily Living - psychology | Foot Dermatoses - psychology | Hand Dermatoses - therapy | Nurse's Role | Attitude to Health | Foot Dermatoses - diagnosis | Foot Dermatoses - therapy | Humans | Psoriasis - diagnosis | Cost of Illness | Antibodies, Monoclonal - therapeutic use | Psoriasis - psychology | Hand Dermatoses - psychology | Health Services Needs and Demand | Mass Screening | Self Concept | Quality of Life - psychology | Hand Dermatoses - diagnosis | Nursing Assessment | Psoriasis - therapy | Services | Care and treatment | Psoriasis | Nurses | Analysis | Diagnosis | Quality of life
Journal Article
Journal of Drugs in Dermatology, ISSN 1545-9616, 05/2016, Volume 15, Issue 5, pp. 562 - 566
Introduction: We evaluated post hoc the relationship between Humira (adalimumab) therapy and high-sensitivity C-reactive protein (hs-CRP) levels in patients...
TRIAL | PLAQUE PSORIASIS | INFLAMMATION | DISEASE | PALMOPLANTAR PSORIASIS | ETANERCEPT | ARTHRITIS | CARE | DERMATOLOGY | Severity of Illness Index | Psoriasis - drug therapy | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Psoriasis - diagnosis | Male | Biomarkers - blood | Hand - pathology | Adalimumab - administration & dosage | C-Reactive Protein - metabolism | Adult | Female | Aged | Foot - pathology | Psoriasis - blood
TRIAL | PLAQUE PSORIASIS | INFLAMMATION | DISEASE | PALMOPLANTAR PSORIASIS | ETANERCEPT | ARTHRITIS | CARE | DERMATOLOGY | Severity of Illness Index | Psoriasis - drug therapy | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Psoriasis - diagnosis | Male | Biomarkers - blood | Hand - pathology | Adalimumab - administration & dosage | C-Reactive Protein - metabolism | Adult | Female | Aged | Foot - pathology | Psoriasis - blood
Journal Article
Skin therapy letter, ISSN 1201-5989, 2007, Volume 12, Issue 9, pp. 4 - 7
Hand and foot psoriasis is a chronic and debilitating disease that manifests as plaque-type or pustular-type lesions. Although the palms and soles represent...
Psoriasis - drug therapy | Psoriasis - physiopathology | T-Lymphocytes - drug effects | Humans | Antibodies, Monoclonal - therapeutic use | CD11a Antigen - drug effects | T-Lymphocytes - immunology | Foot Diseases - physiopathology | Hand | Foot Diseases - drug therapy
Psoriasis - drug therapy | Psoriasis - physiopathology | T-Lymphocytes - drug effects | Humans | Antibodies, Monoclonal - therapeutic use | CD11a Antigen - drug effects | T-Lymphocytes - immunology | Foot Diseases - physiopathology | Hand | Foot Diseases - drug therapy
Journal Article
Dermatology Times, ISSN 0196-6197, 05/2007, Volume 28, p. S14
St. Louis - Results of a phase 4, multicenter, randomized, placebocontrolled, double-blind study support the use of efalîzumab (Raptiva, Genentech) as a safe...
Statistical data | Hands | Psoriasis | Light therapy | Drug therapy | Feet
Statistical data | Hands | Psoriasis | Light therapy | Drug therapy | Feet
Trade Publication Article
12.
Full Text
Efalizumab for severe palmo‐plantar psoriasis: an open‐label pilot trial in five patients
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 04/2009, Volume 23, Issue 4, pp. 415 - 419
Background Palmo‐plantar psoriasis (PPP) is a disabling condition that significantly impairs quality of life. PPP tends to be resistant to conventional...
palmo‐plantar psoriasis | efalizumab | psoriasis | PPPASI | Palmo-plantar psoriasis | Efalizumab | Psoriasis | PUSTULAR PSORIASIS | EFFICACY | ALEFACEPT | SAFETY | palmo-plantar psoriasis | RECALCITRANT PALMOPLANTAR | FOOT PSORIASIS | HAND | DERMATOLOGY | Pilot Projects | Psoriasis - drug therapy | Humans | Middle Aged | Adult | Antibodies, Monoclonal - therapeutic use | Female | Male | Aged | Cell Migration Inhibition | Monoclonal antibodies | Retinoids | Psoralens | Public-private sector cooperation
palmo‐plantar psoriasis | efalizumab | psoriasis | PPPASI | Palmo-plantar psoriasis | Efalizumab | Psoriasis | PUSTULAR PSORIASIS | EFFICACY | ALEFACEPT | SAFETY | palmo-plantar psoriasis | RECALCITRANT PALMOPLANTAR | FOOT PSORIASIS | HAND | DERMATOLOGY | Pilot Projects | Psoriasis - drug therapy | Humans | Middle Aged | Adult | Antibodies, Monoclonal - therapeutic use | Female | Male | Aged | Cell Migration Inhibition | Monoclonal antibodies | Retinoids | Psoralens | Public-private sector cooperation
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 12/2012, Volume 39, Issue 12, pp. 1076 - 1077
CARCINOMA | DERMATOLOGY | Niacinamide - analogs & derivatives | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Humans | Middle Aged | Psoriasis - chemically induced | Ultraviolet Therapy | Niacinamide - adverse effects | Hand-Foot Syndrome - radiotherapy | Psoriasis - radiotherapy | Male | Hand-Foot Syndrome - etiology | Psoriasis | Skin | Phototherapy
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 07/2014, Volume 28, Issue 7, pp. 882 - 890
Background The Randomized Controlled Evaluation of Adalimumab in Treatment of Chronic Plaque Psoriasis of the Hands and Feet (REACH) trial demonstrated that...
NAIL PSORIASIS | PLACEBO | MANAGEMENT | SAFETY | ALEFACEPT | USTEKINUMAB | RECALCITRANT PALMOPLANTAR | DOUBLE-BLIND | PALMOPLANTAR PSORIASIS | QUALITY-OF-LIFE | DERMATOLOGY | Severity of Illness Index | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Double-Blind Method | Outcome Assessment (Health Care) | Humans | Middle Aged | Male | Treatment Outcome | Hand | Foot | Dose-Response Relationship, Drug | Time Factors | Endpoint Determination | Anti-Inflammatory Agents - therapeutic use | Adult | Female | Aged | Adalimumab | Chronic Disease | Dermatologic agents | Psoriasis | Dermatology | Analysis | Formulae, receipts, prescriptions | Original
NAIL PSORIASIS | PLACEBO | MANAGEMENT | SAFETY | ALEFACEPT | USTEKINUMAB | RECALCITRANT PALMOPLANTAR | DOUBLE-BLIND | PALMOPLANTAR PSORIASIS | QUALITY-OF-LIFE | DERMATOLOGY | Severity of Illness Index | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Double-Blind Method | Outcome Assessment (Health Care) | Humans | Middle Aged | Male | Treatment Outcome | Hand | Foot | Dose-Response Relationship, Drug | Time Factors | Endpoint Determination | Anti-Inflammatory Agents - therapeutic use | Adult | Female | Aged | Adalimumab | Chronic Disease | Dermatologic agents | Psoriasis | Dermatology | Analysis | Formulae, receipts, prescriptions | Original
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 12/2014, Volume 28, Issue 12, pp. 1670 - 1675
Background Psoriasis affecting sites such as the hands, feet and nails can be particularly difficult to treat. There are limited data on the efficacy of...
THERAPY | EFFICACY | ADALIMUMAB | SAFETY | USTEKINUMAB | ETANERCEPT | DERMATOLOGY | Psoriasis - drug therapy | Double-Blind Method | Psoriasis - pathology | Humans | Placebos | Antibodies, Monoclonal - therapeutic use | Foot - pathology | Hand - pathology | Nails - pathology | Biological products | Psoriasis | Dermatology | Formulae, receipts, prescriptions | Clinical trials | Dermatologic agents | Product development
THERAPY | EFFICACY | ADALIMUMAB | SAFETY | USTEKINUMAB | ETANERCEPT | DERMATOLOGY | Psoriasis - drug therapy | Double-Blind Method | Psoriasis - pathology | Humans | Placebos | Antibodies, Monoclonal - therapeutic use | Foot - pathology | Hand - pathology | Nails - pathology | Biological products | Psoriasis | Dermatology | Formulae, receipts, prescriptions | Clinical trials | Dermatologic agents | Product development
Journal Article
Dermatologic Therapy, ISSN 1396-0296, 05/2018, Volume 31, Issue 3, pp. e12589 - n/a
Psoriasis of the scalp, face, intertriginous areas, genitals, hands, feet, and nails is often underdiagnosed, and disease management can be challenging....
nails | psoriasis | review | scalp | intertriginous | treatment options | clinical studies | difficult to treat psoriasis | quality of life | palmoplantar | psoriasis of the extremities | TO-SEVERE PSORIASIS | SKIN-DISEASE | RANDOMIZED CONTROLLED-TRIAL | DERMATOLOGY | ORAL PHOSPHODIESTERASE-4 INHIBITOR | SEVERE PLAQUE PSORIASIS | DOUBLE-BLIND | PALMOPLANTAR PSORIASIS | OPEN-LABEL TRIAL | QUALITY-OF-LIFE | FACIAL PSORIASIS | Genital Diseases, Female - therapy | Hand Dermatoses - therapy | Facial Dermatoses - therapy | Foot Dermatoses - therapy | Genital Diseases, Male - therapy | Humans | Psoriasis - diagnosis | Female | Male | Nail Diseases - therapy | Scalp Dermatoses - therapy | Psoriasis - therapy | Medical research | Psoriasis | Dermatology | Formulae, receipts, prescriptions | Medicine, Experimental | Dermatologic agents | Diagnosis
nails | psoriasis | review | scalp | intertriginous | treatment options | clinical studies | difficult to treat psoriasis | quality of life | palmoplantar | psoriasis of the extremities | TO-SEVERE PSORIASIS | SKIN-DISEASE | RANDOMIZED CONTROLLED-TRIAL | DERMATOLOGY | ORAL PHOSPHODIESTERASE-4 INHIBITOR | SEVERE PLAQUE PSORIASIS | DOUBLE-BLIND | PALMOPLANTAR PSORIASIS | OPEN-LABEL TRIAL | QUALITY-OF-LIFE | FACIAL PSORIASIS | Genital Diseases, Female - therapy | Hand Dermatoses - therapy | Facial Dermatoses - therapy | Foot Dermatoses - therapy | Genital Diseases, Male - therapy | Humans | Psoriasis - diagnosis | Female | Male | Nail Diseases - therapy | Scalp Dermatoses - therapy | Psoriasis - therapy | Medical research | Psoriasis | Dermatology | Formulae, receipts, prescriptions | Medicine, Experimental | Dermatologic agents | Diagnosis
Journal Article
Clinical Rheumatology, ISSN 0770-3198, 2/2018, Volume 37, Issue 2, pp. 383 - 388
We evaluated inflammation at the small joints of feet in psoriasis patients without clinical arthritis (PsO) as against clinically overt psoriatic arthritis...
Inflammation | Medicine & Public Health | Magnetic resonance imaging | Psoriasis | Rheumatology | Psoriatic arthritis | PREVALENCE | RHEUMATOLOGY | EPIDEMIOLOGY | HAND | FOOT | SYNOVITIS | FEATURES | Medicine, Experimental | Medical research | Medical colleges | Arthritis | Synovitis | Nuclear magnetic resonance--NMR | Osteitis | Tenosynovitis | Joint diseases | Risk factors | Feet
Inflammation | Medicine & Public Health | Magnetic resonance imaging | Psoriasis | Rheumatology | Psoriatic arthritis | PREVALENCE | RHEUMATOLOGY | EPIDEMIOLOGY | HAND | FOOT | SYNOVITIS | FEATURES | Medicine, Experimental | Medical research | Medical colleges | Arthritis | Synovitis | Nuclear magnetic resonance--NMR | Osteitis | Tenosynovitis | Joint diseases | Risk factors | Feet
Journal Article